Systemic lupus erythematosus: pathogenesis and targeted therapy.

Humans Lupus Erythematosus, Systemic / immunology Molecular Targeted Therapy / methods Animals Immunosuppressive Agents / therapeutic use
Autoimmune diseases Pathogenesis Systemic lupus erythematosus Targeted therapeutic strategies

Journal

Molecular biomedicine
ISSN: 2662-8651
Titre abrégé: Mol Biomed
Pays: Singapore
ID NLM: 9918283581406676

Informations de publication

Date de publication:
30 Oct 2024
Historique:
received: 14 07 2024
accepted: 16 10 2024
medline: 30 10 2024
pubmed: 30 10 2024
entrez: 30 10 2024
Statut: epublish

Résumé

Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by dysregulated immune responses and autoantibody production, which affects multiple organs and varies in clinical presentation and disease severity. The development of SLE is intricate, encompassing dysregulation within the immune system, a collapse of immunological tolerance, genetic susceptibilities to the disease, and a variety of environmental factors that can act as triggers. This review provides a comprehensive discussion of the pathogenesis and treatment strategies of SLE and focuses on the progress and status of traditional and emerging treatment strategies for SLE. Traditional treatment strategies for SLE have mainly employed non-specific approaches, including cytotoxic and immunosuppressive drugs, antimalarials, glucocorticoids, and NSAIDs. These strategies are effective in mitigating the effects of the disease, but they are not a complete cure and are often accompanied by adverse reactions. Emerging targeted therapeutic drugs, on the other hand, aim to control and treat SLE by targeting B and T cells, inhibiting their activation and function, as well as the abnormal activation of the immune system. A deeper understanding of the pathogenesis of SLE and the exploration of new targeted treatment strategies are essential to advance the treatment of this complex autoimmune disease.

Identifiants

DOI: 10.1186/s43556-024-00217-8 PMID: 39472388
pubmed: 39472388
doi: 10.1186/s43556-024-00217-8
pii: 10.1186/s43556-024-00217-8
doi:

Substances chimiques

Immunosuppressive Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

54

Subventions

Organisme : National Natural Science Foundation of China
ID : 82303238
Organisme : The Third People's Hospital of Chengdu Scientific Research Project
ID : 2023PI18

Informations de copyright

© 2024. The Author(s).

Références

Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med. 2020;172(11):Itc81-96. https://doi.org/10.7326/aitc202006020 .
doi: 10.7326/aitc202006020 pubmed: 32479157
Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019;96:1–13. https://doi.org/10.1016/j.jaut.2018.11.001 .
doi: 10.1016/j.jaut.2018.11.001 pubmed: 30448290
Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet (London England). 2019;393(10188):2344–58. https://doi.org/10.1016/s0140-6736(19)30546-x .
doi: 10.1016/s0140-6736(19)30546-x pubmed: 31180031
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–45. https://doi.org/10.1136/annrheumdis-2019-215089 .
doi: 10.1136/annrheumdis-2019-215089 pubmed: 30926722
Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14–25. https://doi.org/10.1136/annrheumdis-2020-218272 .
doi: 10.1136/annrheumdis-2020-218272 pubmed: 33051219
Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet (London England). 2019;393(10188):2332–43. https://doi.org/10.1016/s0140-6736(19)30237-5 .
doi: 10.1016/s0140-6736(19)30237-5 pubmed: 31180030
Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (Natural Interferon- α/β-Producing cells) Accumulate in Cutaneous Lupus Erythematosus lesions. Am J Pathol. 2001;159(1):237–43. https://doi.org/10.1016/s0002-9440(10)61689-6 .
doi: 10.1016/s0002-9440(10)61689-6 pubmed: 11438470 pmcid: 1850412
Macedo ACL, Isaac L. Systemic lupus erythematosus and deficiencies of Early Components of the complement classical pathway. Front Immunol. 2016;7:7. https://doi.org/10.3389/fimmu.2016.00055 .
doi: 10.3389/fimmu.2016.00055
Yap DYH, Chan TM. B cell abnormalities in systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of immunosuppressive treatments. Int J Mol Sci. 2019;20(24): 6231. https://doi.org/10.3390/ijms20246231 .
doi: 10.3390/ijms20246231 pubmed: 31835612 pmcid: 6940927
Tsokos GC, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716–30. https://doi.org/10.1038/nrrheum.2016.186 .
doi: 10.1038/nrrheum.2016.186 pubmed: 27872476
Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune Interferon in the circulation of patients with Autoimmune Disease. N Engl J Med. 1979;301(1):5–8. https://doi.org/10.1056/nejm197907053010102 .
doi: 10.1056/nejm197907053010102 pubmed: 449915
Zhong J, Zheng C, Chen Z, Yue H, Gao H, Jiang Y, et al. Phosphopeptides P140 cause oxidative burst responses of pulmonary macrophages in an imiquimod-induced lupus model. Mol Biomed. 2023;4(1):38. https://doi.org/10.1186/s43556-023-00149-9 .
doi: 10.1186/s43556-023-00149-9 pubmed: 37922035 pmcid: 10624795
Robinson R, Distinct B. Cell receptor functions are determined by phosphorylation. PLoS Biol. 2006;4(7):e231. https://doi.org/10.1371/journal.pbio.0040231 .
doi: 10.1371/journal.pbio.0040231 pubmed: 20076604 pmcid: 1470464
Nemazee D. Mechanisms of central tolerance for B cells. Nat Rev Immunol. 2017;17(5):281–94. https://doi.org/10.1038/nri.2017.19 .
doi: 10.1038/nri.2017.19 pubmed: 28368006 pmcid: 5623591
Zikherman J, Parameswaran R, Weiss A. Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature. 2012;489(7414):160–4. https://doi.org/10.1038/nature11311 .
doi: 10.1038/nature11311 pubmed: 22902503 pmcid: 3438375
Burnett DL, Langley DB, Schofield P, Hermes JR, Chan TD, Jackson J, et al. Germinal center antibody mutation trajectories are determined by rapid self/foreign discrimination. Science. 2018;360(6385):223–6. https://doi.org/10.1126/science.aao3859 .
doi: 10.1126/science.aao3859 pubmed: 29650674 pmcid: 5922412
Lin L, Yu H, Li L, Yang W, Chen X, Gong Y, et al. TRIM55 promotes noncanonical NF-κB signaling and B cell-mediated immune responses by coordinating p100 ubiquitination and processing. Sci Signal. 2023;16(806): eabn5410. https://doi.org/10.1126/scisignal.abn5410 .
doi: 10.1126/scisignal.abn5410 pubmed: 37816088
Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491–502. https://doi.org/10.1038/nri2572 .
doi: 10.1038/nri2572 pubmed: 19521398
Jackson SW, Davidson A. BAFF inhibition in SLE—Is tolerance restored? Immunol Rev. 2019;292(1):102–19. https://doi.org/10.1111/imr.12810 .
doi: 10.1111/imr.12810 pubmed: 31562657 pmcid: 6935406
Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell Richard A, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing Inflammatory and Regulatory roles in a murine model of Lupus. Immunity. 2006;25(3):417–28. https://doi.org/10.1016/j.immuni.2006.07.013 .
doi: 10.1016/j.immuni.2006.07.013 pubmed: 16973389
Berland R, Fernandez L, Kari E, Han J-H, Lomakin I, Akira S, et al. Toll-like receptor 7-Dependent loss of B Cell Tolerance in Pathogenic Autoantibody Knockin mice. Immunity. 2006;25(3):429–40. https://doi.org/10.1016/j.immuni.2006.07.014 .
doi: 10.1016/j.immuni.2006.07.014 pubmed: 16973388
Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med. 2005;202(2):321–31. https://doi.org/10.1084/jem.20050338 .
doi: 10.1084/jem.20050338 pubmed: 16027240 pmcid: 2212997
Lartigue A, Courville P, Auquit I, François A, Arnoult C, Tron F, et al. Role of TLR9 in Anti-nucleosome and Anti-DNA antibody production in lpr Mutation-Induced Murine Lupus. J Immunol. 2006;177(2):1349–54. https://doi.org/10.4049/jimmunol.177.2.1349 .
doi: 10.4049/jimmunol.177.2.1349 pubmed: 16818796
Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15(3):160–71. https://doi.org/10.1038/nri3795 .
doi: 10.1038/nri3795 pubmed: 25698678
Vinuesa CG, Sanz I, Cook MC. Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol. 2009;9(12):845–57. https://doi.org/10.1038/nri2637 .
doi: 10.1038/nri2637 pubmed: 19935804
Chan O, Shlomchik J. A New Role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lprMice. J Immunol. 1998;160(1):51–9. https://doi.org/10.4049/jimmunol.160.1.51 .
doi: 10.4049/jimmunol.160.1.51 pubmed: 9551955
Chan OTM, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A Novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999;189(10):1639–48. https://doi.org/10.1084/jem.189.10.1639 .
doi: 10.1084/jem.189.10.1639 pubmed: 10330443 pmcid: 2193634
Shah D, Kiran R, Wanchu A, Bhatnagar A. Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity. Immunol Lett. 2010;129(1):7–12. https://doi.org/10.1016/j.imlet.2010.01.005 .
doi: 10.1016/j.imlet.2010.01.005 pubmed: 20105444
Sugimoto K, Morimoto S, Kaneko H, Nozawa K, Tokano Y, Takasaki Y, et al. Decreased IL-4 producing CD4 + T cells in patients with active systemic lupus erythematosus-relation to IL-12R expression. Autoimmunity. 2009;35(6):381–7. https://doi.org/10.1080/0891693021000008535 .
doi: 10.1080/0891693021000008535
Paroli M, Caccavale R, Fiorillo MT, Spadea L, Gumina S, Candela V, et al. The double game played by Th17 cells in infection: Host Defense and immunopathology. Pathogens. 2022;11(12): 1547. https://doi.org/10.3390/pathogens11121547 .
doi: 10.3390/pathogens11121547 pubmed: 36558881 pmcid: 9781511
López P, Rodríguez-Carrio J, Caminal-Montero L, Mozo L, Suárez A. A pathogenic IFNα, BLyS and IL-17 axis in systemic Lupus Erythematosus patients. Sci Rep. 2016;6(1): 20651. https://doi.org/10.1038/srep20651 .
doi: 10.1038/srep20651 pubmed: 26847824 pmcid: 4742957
Zickert A, Amoudruz P, Sundström Y, Rönnelid J, Malmström V, Gunnarsson I. IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol. 2015;16(1): 7. https://doi.org/10.1186/s12865-015-0070-7 .
doi: 10.1186/s12865-015-0070-7 pubmed: 25887118 pmcid: 4326189
Bonelli M, Savitskaya A, von Dalwigk K, Steiner CW, Aletaha D, Smolen JS, et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol. 2008;20(7):861–8. https://doi.org/10.1093/intimm/dxn044 .
doi: 10.1093/intimm/dxn044 pubmed: 18469329
Alexander T, Sattler A, Templin L, Kohler S, Groß C, Meisel A, et al. Foxp3 + helios + regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis. 2013;72(9):1549–58. https://doi.org/10.1136/annrheumdis-2012-202216 .
doi: 10.1136/annrheumdis-2012-202216 pubmed: 23264341
La Cava A. Tregs in SLE: an update. Curr Rheumatol Rep. 2018;20(2): 6. https://doi.org/10.1007/s11926-018-0714-8 .
doi: 10.1007/s11926-018-0714-8 pubmed: 29464438
Chen P-M, Tsokos GC. T cell abnormalities in the pathogenesis of systemic Lupus Erythematosus: an update. Curr Rheumatol Rep. 2021;23(2): 12. https://doi.org/10.1007/s11926-020-00978-5 .
doi: 10.1007/s11926-020-00978-5 pubmed: 33512577 pmcid: 8601587
Liarski VM, Kaverina N, Chang A, Brandt D, Yanez D, Talasnik L et al. Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue. Sci Transl Med. 2014;6(230). https://doi.org/10.1126/scitranslmed.3008146 .
Comte D, Karampetsou MP, Yoshida N, Kis-Toth K, Kyttaris VC, Tsokos GC. Signaling lymphocytic activation Molecule Family Member 7 Engagement restores defective Effector CD8 + T cell function in systemic Lupus Erythematosus. Arthritis Rheumatol. 2017;69(5):1035–44. https://doi.org/10.1002/art.40038 .
doi: 10.1002/art.40038 pubmed: 28076903 pmcid: 5406259
McKinney EF, Lee JC, Jayne DRW, Lyons PA, Smith KGC. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523(7562):612–6. https://doi.org/10.1038/nature14468 .
doi: 10.1038/nature14468 pubmed: 26123020 pmcid: 4623162
Katsuyama E, Suarez-Fueyo A, Bradley SJ, Mizui M, Marin AV, Mulki L, et al. The CD38/NAD/SIRTUIN1/EZH2 Axis mitigates cytotoxic CD8 T cell function and identifies patients with SLE prone to infections. Cell Rep. 2020;30(1):112-e234. https://doi.org/10.1016/j.celrep.2019.12.014 .
doi: 10.1016/j.celrep.2019.12.014 pubmed: 31914379 pmcid: 7577012
Li X, Kang N, Zhang X, Dong X, Wei W, Cui L, et al. Generation of Human Regulatory γδ T cells by TCRγδ Stimulation in the Presence of TGF-β and their involvement in the pathogenesis of systemic Lupus Erythematosus. J Immunol. 2011;186(12):6693–700. https://doi.org/10.4049/jimmunol.1002776 .
doi: 10.4049/jimmunol.1002776 pubmed: 21562160
Robak E, Niewiadomska H, Robak T, Bartkowiak J, Bloński JZ, Woźniacka A, et al. Lymphocytes Tγδ in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity. Mediat Inflamm. 2001;10(4):179–89. https://doi.org/10.1080/09629350124724 .
doi: 10.1080/09629350124724
Brandt L, Hedberg H. Impaired phagocytosis by peripheral blood granulocytes in systemic lupus erythematosus. Scandinavian J Haematol. 2009;6(5):348–53. https://doi.org/10.1111/j.1600-0609.1969.tb02420.x .
doi: 10.1111/j.1600-0609.1969.tb02420.x
Donnelly S, Roake W, Brown S, Young P, Naik H, Wordsworth P, et al. Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. Arthr Rhuem. 2006;54(5):1543–56. https://doi.org/10.1002/art.21783 .
doi: 10.1002/art.21783
Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, Smith CK, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. 2016;22(2):146–53. https://doi.org/10.1038/nm.4027 .
doi: 10.1038/nm.4027 pubmed: 26779811 pmcid: 4742415
Lindau D, Mussard J, Rabsteyn A, Ribon M, Kötter I, Igney A, et al. TLR9 independent interferon α production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen. Ann Rheum Dis. 2014;73(12):2199–207. https://doi.org/10.1136/annrheumdis-2012-203041 .
doi: 10.1136/annrheumdis-2012-203041 pubmed: 24013727
Palanichamy A, Bauer JW, Yalavarthi S, Meednu N, Barnard J, Owen T, et al. Neutrophil-mediated IFN activation in the bone marrow alters B Cell Development in Human and Murine systemic lupus erythematosus. J Immunol. 2014;192(3):906–18. https://doi.org/10.4049/jimmunol.1302112 .
doi: 10.4049/jimmunol.1302112 pubmed: 24379124
Rahman S, Sagar D, Hanna RN, Lightfoot YL, Mistry P, Smith CK, et al. Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann Rheum Dis. 2019;78(7):957–66. https://doi.org/10.1136/annrheumdis-2018-214620 .
doi: 10.1136/annrheumdis-2018-214620 pubmed: 31040119
Midgley A, Beresford MW. Increased expression of low density granulocytes in juvenile-onset systemic lupus erythematosus patients correlates with disease activity. Lupus. 2015;25(4):407–11. https://doi.org/10.1177/0961203315608959 .
doi: 10.1177/0961203315608959 pubmed: 26453665
Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, et al. A distinct subset of Proinflammatory neutrophils isolated from patients with systemic Lupus Erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol. 2010;184(6):3284–97. https://doi.org/10.4049/jimmunol.0902199 .
doi: 10.4049/jimmunol.0902199 pubmed: 20164424
Boeltz S, Amini P, Anders H-J, Andrade F, Bilyy R, Chatfield S, et al. To NET or not to NET:current opinions and state of the science regarding the formation of neutrophil extracellular traps. Cell Death Differ. 2019;26(3):395–408. https://doi.org/10.1038/s41418-018-0261-x .
doi: 10.1038/s41418-018-0261-x pubmed: 30622307 pmcid: 6370810
Apel F, Zychlinsky A, Kenny EF. The role of neutrophil extracellular traps in rheumatic diseases. Nat Rev Rheumatol. 2018;14(8):467–75. https://doi.org/10.1038/s41584-018-0039-z .
doi: 10.1038/s41584-018-0039-z pubmed: 29930301
Odqvist L, Jevnikar Z, Riise R, Öberg L, Rhedin M, Leonard D, et al. Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. Ann Rheum Dis. 2019;78(10):1363–70. https://doi.org/10.1136/annrheumdis-2019-215434 .
doi: 10.1136/annrheumdis-2019-215434 pubmed: 31300459
Chang HH, Dwivedi N, Nicholas AP, Ho IC. The W620 polymorphism in PTPN22 disrupts its Interaction with Peptidylarginine Deiminase Type 4 and enhances citrullination and NETosis. Arthritis Rheumatol. 2015;67(9):2323–34. https://doi.org/10.1002/art.39215 .
doi: 10.1002/art.39215 pubmed: 26019128
Li D, Matta B, Song S, Nelson V, Diggins K, Simpfendorfer KR et al. IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE. JCI Insight. 2020;5(2). https://doi.org/10.1172/jci.insight.124020 .
Goel RR, Nakabo S, Dizon BLP, Urban A, Waldman M, Howard L, et al. Lupus-like autoimmunity and increased interferon response in patients with STAT3-deficient hyper-IgE syndrome. J Allergy Clin Immunol. 2021;147(2):746. https://doi.org/10.1016/j.jaci.2020.07.024 .
doi: 10.1016/j.jaci.2020.07.024 pubmed: 32768442
Kahlenberg JM, Carmona-Rivera C, Smith CK, Kaplan MJ. Neutrophil Extracellular Trap–Associated protein activation of the NLRP3 inflammasome is enhanced in Lupus macrophages. J Immunol. 2013;190(3):1217–26. https://doi.org/10.4049/jimmunol.1202388 .
doi: 10.4049/jimmunol.1202388 pubmed: 23267025
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–52. https://doi.org/10.1038/32588 .
doi: 10.1038/32588 pubmed: 9521319
Ganguly D, Haak S, Sisirak V, Reizis B. The role of dendritic cells in autoimmunity. Nat Rev Immunol. 2013;13(8):566–77. https://doi.org/10.1038/nri3477 .
doi: 10.1038/nri3477 pubmed: 23827956 pmcid: 4160805
Broz P, Monack DM. Newly described pattern recognition receptors team up against intracellular pathogens. Nat Rev Immunol. 2013;13(8):551–65. https://doi.org/10.1038/nri3479 .
doi: 10.1038/nri3479 pubmed: 23846113
Crispín JC, Vargas-Rojas MI, Monsiváis-Urenda A, Alcocer-Varela J. Phenotype and function of dendritic cells of patients with systemic lupus erythematosus. Clin Immunol. 2012;143(1):45–50. https://doi.org/10.1016/j.clim.2011.12.004 .
doi: 10.1016/j.clim.2011.12.004 pubmed: 22239954
Ding D, Mehta H, McCune WJ, Kaplan MJ. Aberrant phenotype and function of myeloid dendritic cells in systemic Lupus Erythematosus. J Immunol. 2006;177(9):5878–89. https://doi.org/10.4049/jimmunol.177.9.5878 .
doi: 10.4049/jimmunol.177.9.5878 pubmed: 17056512
Das A, Heesters BA, Bialas A, O’Flynn J, Rifkin IR, Ochando J, et al. Follicular dendritic cell activation by TLR ligands promotes autoreactive B cell responses. Immunity. 2017;46(1):106–19. https://doi.org/10.1016/j.immuni.2016.12.014 .
doi: 10.1016/j.immuni.2016.12.014 pubmed: 28099860 pmcid: 8140609
Sisirak V, Ganguly D, Lewis KL, Couillault C, Tanaka L, Bolland S, et al. Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus. J Exp Med. 2014;211(10):1969–76. https://doi.org/10.1084/jem.20132522 .
doi: 10.1084/jem.20132522 pubmed: 25180061 pmcid: 4172218
Fiore N, Castellano G, Blasi A, Capobianco C, Loverre A, Montinaro V, et al. Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Mol Immunol. 2008;45(1):259–65. https://doi.org/10.1016/j.molimm.2007.04.029 .
doi: 10.1016/j.molimm.2007.04.029 pubmed: 17570528
Sakata K, Nakayamada S, Miyazaki Y, Kubo S, Ishii A, Nakano K, et al. Up-Regulation of TLR7-Mediated IFN-α production by Plasmacytoid dendritic cells in patients with systemic Lupus Erythematosus. Front Immunol. 2018;9:9. https://doi.org/10.3389/fimmu.2018.01957 .
doi: 10.3389/fimmu.2018.01957
Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res. Therapy. 2003;5(6):279. https://doi.org/10.1186/ar1015 .
doi: 10.1186/ar1015
Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2013;14(1):36–49. https://doi.org/10.1038/nri3581 .
doi: 10.1038/nri3581
Chyuan IT, Tzeng H-T, Chen J-Y. Signaling pathways of type I and type III interferons and targeted therapies in systemic Lupus Erythematosus. Cells. 2019;8(9): 963. https://doi.org/10.3390/cells8090963 .
doi: 10.3390/cells8090963 pubmed: 31450787 pmcid: 6769759
Liu Y-JIPC. Professional Type 1 Interferon-Producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005;23(1):275–306. https://doi.org/10.1146/annurev.immunol.23.021704.115633 .
doi: 10.1146/annurev.immunol.23.021704.115633 pubmed: 15771572
Petro TM. IFN Regulatory Factor 3 in Health and Disease. J Immunol. 2020;205(8):1981–9. https://doi.org/10.4049/jimmunol.2000462 .
doi: 10.4049/jimmunol.2000462 pubmed: 33020188
Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 Interferon-Producing cells in human blood. Science. 1999;284(5421):1835–7. https://doi.org/10.1126/science.284.5421.1835 .
doi: 10.1126/science.284.5421.1835 pubmed: 10364556
Schoggins JW. Interferon-stimulated genes: what do they all do? Ann Rev Virol. 2019;6(1):567–84. https://doi.org/10.1146/annurev-virology-092818-015756 .
doi: 10.1146/annurev-virology-092818-015756
Stark George R, Darnell James E. The JAK-STAT pathway at twenty. Immunity. 2012;36(4):503–14. https://doi.org/10.1016/j.immuni.2012.03.013 .
doi: 10.1016/j.immuni.2012.03.013 pubmed: 22520844 pmcid: 3909993
Teinberg AD, Baron S, Talal N. The pathogenesis of autoimmunity in new zealand mice, i. induction of antinucleic acid antibodies by polyinosinic·polycytidylic acid. Proceed National Acad Sci. 1969;63(4):1102–7.
doi: 10.1073/pnas.63.4.1102
Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25(3):283–91. https://doi.org/10.1016/s0168-8278(96)80113-9 .
doi: 10.1016/s0168-8278(96)80113-9 pubmed: 8895006
Gota C, Calabrese L. Induction of Clinical Autoimmune Disease by Therapeutic Interferon-α. Autoimmunity. 2009;36(8):511–8. https://doi.org/10.1080/08916930310001605873 .
doi: 10.1080/08916930310001605873
Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol. 2004;24(2):178–81. https://doi.org/10.1007/s10067-004-1024-2 .
doi: 10.1007/s10067-004-1024-2 pubmed: 15565395
Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum. 2002;32(3):163–73. https://doi.org/10.1053/sarh.2002.37277 .
doi: 10.1053/sarh.2002.37277 pubmed: 12528081
Graham RR, Kozyrev SV, Baechler EC, Reddy MVPL, Plenge RM, Bauer JW, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet. 2006;38(5):550–5. https://doi.org/10.1038/ng1782 .
doi: 10.1038/ng1782 pubmed: 16642019
Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;40(2):204–10. https://doi.org/10.1038/ng.81 .
doi: 10.1038/ng.81 pubmed: 18204446 pmcid: 3712260
Lessard Christopher J, Adrianto I, Ice John A, Wiley Graham B, Kelly Jennifer A, Glenn Stuart B, et al. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic Lupus Erythematosus in a large-scale multiracial replication study. Am J Hum Genet. 2012;90(4):648–60. https://doi.org/10.1016/j.ajhg.2012.02.023 .
doi: 10.1016/j.ajhg.2012.02.023 pubmed: 22464253 pmcid: 3322228
Ghodke-Puranik Y, Niewold TB. Genetics of the type I interferon pathway in systemic lupus erythematosus. Int J Clin Rheumatol. 2013;8(6):657–69. https://doi.org/10.2217/ijr.13.58 .
doi: 10.2217/ijr.13.58
Järvinen P, Aho K. Twin studies in rheumatic diseases. Semin Arthritis Rheum. 1994;24(1):19–28. https://doi.org/10.1016/0049-0172(94)90096-5 .
doi: 10.1016/0049-0172(94)90096-5 pubmed: 7985034
Karassa FB, Trikalinos TA, Ioannidis JPA. The role of FcγRIIA and IIIA polymorphisms in autoimmune diseases. Biomed Pharmacother. 2004;58(5):286–91. https://doi.org/10.1016/j.biopha.2004.04.004 .
doi: 10.1016/j.biopha.2004.04.004 pubmed: 15194164
Kyogoku C, Ortmann WA, Lee A, Selby S, Carlton VEH, Chang M, et al. Genetic Association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004;75(3):504–7. https://doi.org/10.1086/423790 .
doi: 10.1086/423790 pubmed: 15273934 pmcid: 1182029
Suarez A. Differential effect of IL10 and TNF genotypes on determining susceptibility to discoid and systemic lupus erythematosus. Ann Rheum Dis. 2005;64(11):1605–10. https://doi.org/10.1136/ard.2004.035048 .
doi: 10.1136/ard.2004.035048 pubmed: 15800006 pmcid: 1755257
Sestak AL, Nath SK, Sawalha AH, Harley JB. Current status of lupus genetics. Arthritis Res Ther. 2007;9(3). https://doi.org/10.1186/ar2176 .
Kim HY, Lee SH, Yang HI, Park SH, Cho CS, Kim TG, et al. TNFB Gene Polymorphism in patients with systemic Lupus Erythematosus in Korean. Korean J Intern Med. 1995;10(2):130–6. https://doi.org/10.3904/kjim.1995.10.2.130 .
doi: 10.3904/kjim.1995.10.2.130 pubmed: 7495771 pmcid: 4532044
Prokunina L, Castillejo-López C, Öberg F, Gunnarsson I, Berg L, Magnusson V, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet. 2002;32(4):666–9. https://doi.org/10.1038/ng1020 .
doi: 10.1038/ng1020 pubmed: 12402038
Parks CG, Hudson LL, Cooper GS, Dooley MA, Treadwell EL, St Clair EW, et al. CTLA-4 gene polymorphisms and systemic lupus erythematosus in a population-based study of whites and african-americans in the southeastern United States. Lupus. 2016;13(10):784–91. https://doi.org/10.1191/0961203304lu1085oa .
doi: 10.1191/0961203304lu1085oa
Zan H, Casali P. Epigenetics of Peripheral B-Cell differentiation and the antibody response. Front Immunol. 2015;6:6. https://doi.org/10.3389/fimmu.2015.00631 .
doi: 10.3389/fimmu.2015.00631
Patel DR, Richardson BC. Dissecting complex epigenetic alterations in human lupus. Arthritis Res Ther. 2012;15(1). https://doi.org/10.1186/ar4125 .
Zhang Y, Zhao M, Sawalha AH, Richardson B, Lu Q. Impaired DNA methylation and its mechanisms in CD4 + T cells of systemic lupus erythematosus. J Autoimmun. 2013;41:92–9. https://doi.org/10.1016/j.jaut.2013.01.005 .
doi: 10.1016/j.jaut.2013.01.005 pubmed: 23340289
Araki Y, Mimura T. Epigenetic dysregulation in the pathogenesis of systemic Lupus Erythematosus. Int J Mol Sci. 2024;25(2): 1019. https://doi.org/10.3390/ijms25021019 .
doi: 10.3390/ijms25021019 pubmed: 38256093 pmcid: 10816225
Castro J, Balada E, Ordi-Ros J, Vilardell-Tarrés M. The complex immunogenetic basis of systemic lupus erythematosus. Autoimmun rev. 2008;7(5):345–51. https://doi.org/10.1016/j.autrev.2008.01.001 .
doi: 10.1016/j.autrev.2008.01.001 pubmed: 18486920
Ghodke-Puranik Y, Niewold TB. Immunogenetics of systemic lupus erythematosus: a comprehensive review. J Autoimmun. 2015;64:125–36. https://doi.org/10.1016/j.jaut.2015.08.004 .
doi: 10.1016/j.jaut.2015.08.004 pubmed: 26324017 pmcid: 4628859
Tanaka Y. State-of‐the‐art treatment of systemic lupus erythematosus. Int J Rheum Dis. 2020;23(4):465–71. https://doi.org/10.1111/1756-185x.13817 .
doi: 10.1111/1756-185x.13817 pubmed: 32134201 pmcid: 7187183
Ho PL, Yadav P, Tran H, Ebegbe R, Gottlieb P, Wei H, et al. Antibodies elicited in response to EBNA-1 May cross-react with dsDNA. PLoS ONE. 2011;6(1). https://doi.org/10.1371/journal.pone.0014488 .
Kemp MG, Lindsey-Boltz LA, Sancar A. UV light potentiates STING (stimulator of Interferon Genes)-dependent Innate Immune Signaling through Deregulation of ULK1 (Unc51-like kinase 1). J Biol Chem. 2015;290(19):12184–94. https://doi.org/10.1074/jbc.M115.649301 .
doi: 10.1074/jbc.M115.649301 pubmed: 25792739 pmcid: 4424351
Umare V, Pradhan V, Nadkar M, Rajadhyaksha A, Patwardhan M, Ghosh KK, et al. Effect of Proinflammatory cytokines (IL-6, TNF-α, and IL-1β) on clinical manifestations in Indian SLE patients. Mediat Inflamm. 2014;2014:1–8. https://doi.org/10.1155/2014/385297 .
doi: 10.1155/2014/385297
Yu C, Chang C, Zhang J. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review. J Autoimmun. 2013;41:34–45. https://doi.org/10.1016/j.jaut.2013.01.007 .
doi: 10.1016/j.jaut.2013.01.007 pubmed: 23380467
Meller S, Winterberg F, Gilliet M, Müller A, Lauceviciute I, Rieker J, et al. Ultraviolet radiation–induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthr Rhuem. 2005;52(5):1504–16. https://doi.org/10.1002/art.21034 .
doi: 10.1002/art.21034
Wolf SJ, Estadt SN, Gudjonsson JE, Kahlenberg JM. Human and murine evidence for mechanisms driving autoimmune photosensitivity. Front Immunol. 2018;9:9. https://doi.org/10.3389/fimmu.2018.02430 .
doi: 10.3389/fimmu.2018.02430
Costa S, Borgogna C, Mondini M, De Andrea M, Meroni PL, Berti E, et al. Redistribution of the nuclear protein IFI16 into the cytoplasm of ultraviolet B-exposed keratinocytes as a mechanism of autoantigen processing. Br J Dermatol. 2011;164(2):282–90. https://doi.org/10.1111/j.1365-2133.2010.10097.x .
doi: 10.1111/j.1365-2133.2010.10097.x pubmed: 20973769
Seelig HP, Ehrfeld H, Renz M. Interferon-γ–inducible protein p16. A new target of antinuclear antibodies in patients with systemic lupus erythematosus. Arthr Rhuem. 2005;37(11):1672–83. https://doi.org/10.1002/art.1780371117 .
doi: 10.1002/art.1780371117
Bijl M. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis. 2006;65(1):57–63. https://doi.org/10.1136/ard.2005.035733 .
doi: 10.1136/ard.2005.035733 pubmed: 15919679
Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthr Rhuem. 1998;41(7):1241–50. https://doi.org/10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H .
doi: 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H
Reefman E, Kuiper H, Jonkman MF, Limburg PC, Kallenberg CGM, Bijl M. Skin sensitivity to UVB irradiation in systemic lupus erythematosus is not related to the level of apoptosis induction in keratinocytes. Rheumatology. 2006;45(5):538–44. https://doi.org/10.1093/rheumatology/kei249 .
doi: 10.1093/rheumatology/kei249 pubmed: 16352635
Jones SK. Ultraviolet radiation (UVR) induces cell-surface Ro/SSA antigen expression by human keratinocytes in vitro: a possible mechanism for the UVR induction of cutaneous lupus lesions. Br J Dermatol. 2008;126(6):546–53. https://doi.org/10.1111/j.1365-2133.1992.tb00098.x .
doi: 10.1111/j.1365-2133.1992.tb00098.x
Hersh AO, Arkin LM, Prahalad S. Immunogenetics of cutaneous lupus erythematosus. Curr Opin Pediatr. 2016;28(4):470–5. https://doi.org/10.1097/mop.0000000000000383 .
doi: 10.1097/mop.0000000000000383 pubmed: 27386968 pmcid: 4962329
Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Reviews Disease Primers. 2016;2(1). https://doi.org/10.1038/nrdp.2016.39 .
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(01):20–8. https://doi.org/10.1136/ard.2008.101766 .
doi: 10.1136/ard.2008.101766 pubmed: 19103632
Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol. 2018;15(1):30–48. https://doi.org/10.1038/s41584-018-0133-2 .
doi: 10.1038/s41584-018-0133-2
Xiong W, Lahita RG. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2013;10(2):97–107. https://doi.org/10.1038/nrrheum.2013.157 .
doi: 10.1038/nrrheum.2013.157 pubmed: 24166241
Chan ESL, Cronstein BN. Methotrexate—how does it really work? Nat Rev Rheumatol. 2010;6(3):175–8. https://doi.org/10.1038/nrrheum.2010.5 .
doi: 10.1038/nrrheum.2010.5 pubmed: 20197777
Islam MN, Hossain M, Haq SA, Alam MN, Ten Klooster PM, Rasker JJ. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis. 2011;15(1):62–8. https://doi.org/10.1111/j.1756-185X.2011.01665.x .
doi: 10.1111/j.1756-185X.2011.01665.x pubmed: 22324948
Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double‐blind, randomized, placebo‐controlled trial. Arthritis Care Res. 2008;59(12):1796–804. https://doi.org/10.1002/art.24068 .
doi: 10.1002/art.24068
Bertsias G, Ioannidis JPA, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67(2):195–205. https://doi.org/10.1136/ard.2007.070367 .
doi: 10.1136/ard.2007.070367 pubmed: 17504841
Hoi A, Igel T, Mok CC, Arnaud L. Systemic lupus erythematosus. Lancet. 2024;403(10441):2326–38. https://doi.org/10.1016/s0140-6736(24)00398-2 .
doi: 10.1016/s0140-6736(24)00398-2 pubmed: 38642569
Shigesaka M, Ito T, Inaba M, Imai K, Yamanaka H, Azuma Y, et al. Mycophenolic acid, the active form of mycophenolate mofetil, interferes with IRF7 nuclear translocation and type I IFN production by plasmacytoid dendritic cells. Arthritis Res Therapy. 2020;22(1). https://doi.org/10.1186/s13075-020-02356-z .
Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis. N Engl J Med. 2005;353(21):2219–28. https://doi.org/10.1056/NEJMoa043731 .
doi: 10.1056/NEJMoa043731 pubmed: 16306519
Palmer SC, Tunnicliffe DJ, Singh-Grewal D, Mavridis D, Tonelli M, Johnson DW, et al. Induction and maintenance immunosuppression treatment of proliferative Lupus Nephritis: A Network Meta-analysis of Randomized trials. Am J Kidney Dis. 2017;70(3):324–36. https://doi.org/10.1053/j.ajkd.2016.12.008 .
doi: 10.1053/j.ajkd.2016.12.008 pubmed: 28233655
Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel‐group clinical trial. Arthr Rhuem. 2009;62(1):211–21. https://doi.org/10.1002/art.25052 .
doi: 10.1002/art.25052
Yahya F, Jasmin R, Ng CT, Cheah TE, Sockalingam S. Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement. Int J Rheum Dis. 2013;16(6):724–30. https://doi.org/10.1111/1756-185x.12179 .
doi: 10.1111/1756-185x.12179 pubmed: 24119227
Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Mitjavila F, Castro Salomó A, et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017;76(9):1575–82. https://doi.org/10.1136/annrheumdis-2016-210882 .
doi: 10.1136/annrheumdis-2016-210882 pubmed: 28450313
You Y, Zhou Z, Wang F, Li J, Liu H, Cheng X, et al. Mycophenolate Mofetil and New-Onset systemic lupus erythematosus. JAMA Netw Open. 2024;7(9). https://doi.org/10.1001/jamanetworkopen.2024.32131 .
Peng L, Wu C, Hong R, Sun Y, Qian J, Zhao J, et al. Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis. Therapeutic Adv Musculoskelet Disease. 2020;12. https://doi.org/10.1177/1759720x20953336 .
Ji L, Xie W, Zhang Z. Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(5):1073–80. https://doi.org/10.1016/j.semarthrit.2020.07.006 .
doi: 10.1016/j.semarthrit.2020.07.006 pubmed: 32911286
Lai Z-W, Kelly R, Winans T, Marchena I, Shadakshari A, Yu J, et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet. 2018;391(10126):1186–96. https://doi.org/10.1016/s0140-6736(18)30485-9 .
doi: 10.1016/s0140-6736(18)30485-9 pubmed: 29551338 pmcid: 5891154
Jiang N, Li M, Zhang H, Duan X, Li X, Fang Y, et al. Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study. Lupus Sci Med. 2022;9(1): e000617. https://doi.org/10.1136/lupus-2021-000617 .
doi: 10.1136/lupus-2021-000617 pubmed: 34980680 pmcid: 8724817
Lander SA, Wallace DJ, Weisman MH. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus. 2016;11(6):340–7. https://doi.org/10.1191/0961203302lu204oa .
doi: 10.1191/0961203302lu204oa
Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24(2):121–32. https://doi.org/10.1016/j.bpg.2009.11.005 .
doi: 10.1016/j.bpg.2009.11.005 pubmed: 20227026
Fessler BJ, Alarcón GS, McGwin G, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthr Rhuem. 2005;52(5):1473–80. https://doi.org/10.1002/art.21039 .
doi: 10.1002/art.21039
Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168–72. https://doi.org/10.1136/ard.2006.068676 .
doi: 10.1136/ard.2006.068676 pubmed: 17389655 pmcid: 1955128
Hage MP, Al-Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Therapeutic Adv Endocrinol Metabolism. 2014;5(4):77–85. https://doi.org/10.1177/2042018814547204 .
doi: 10.1177/2042018814547204
dos Reis Neto ET, Kakehasi AM, de Medeiros Pinheiro M, Ferreira GA, Marques CDL, da Mota LMH, et al. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Adv Rheumatol. 2020;60(1). https://doi.org/10.1186/s42358-020-00134-8 .
Stapley L. Bone loss prevention by an antimalarial drug. Trends Endocrinol Metab. 2001;12(4). https://doi.org/10.1016/s1043-2760(01)00396-4 .
Ruiz-Irastorza G, Ugarte A, Egurbide MV, Garmendia M, Pijoan JI, Martinez-Berriotxoa A, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis. 2007;66(6):815–7. https://doi.org/10.1136/ard.2006.067777 .
doi: 10.1136/ard.2006.067777 pubmed: 17204564 pmcid: 1954667
Monzavi SM, Alirezaei A, Shariati-Sarabi Z, Tavakol Afshari J, Mahmoudi M, Dormanesh B, et al. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers. Inflammopharmacology. 2018;26(5):1175–82. https://doi.org/10.1007/s10787-018-0512-y .
doi: 10.1007/s10787-018-0512-y pubmed: 29987550
Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double‐blind, placebo‐controlled trial. Arthr Rhuem. 2006;54(11):3623–32. https://doi.org/10.1002/art.22198 .
doi: 10.1002/art.22198
Guidelines for referral and management of systemic lupus erythematosus in adults. Arthr Rhuem. 2001;42(9):1785–96. https://doi.org/10.1002/1529-0131(199909)42:9<1785::Aid-anr1>3.0.Co;2-# .
Elbirt D, Sthoeger D, Asher I, Sthoeger ZM. The management of systemic lupus erythematosus: facts and controversies. Clin Dermatol. 2010;28(3):330–6. https://doi.org/10.1016/j.clindermatol.2009.06.017 .
doi: 10.1016/j.clindermatol.2009.06.017 pubmed: 20541688
Parker BJ, Bruce IN. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus. 2016;16(6):387–93. https://doi.org/10.1177/0961203307079502 .
doi: 10.1177/0961203307079502
Little J, Parker B, Lunt M, Hanly JG, Urowitz MB, Clarke AE, et al. Glucocorticoid use and factors associated with variability in this use in the systemic Lupus International collaborating clinics Inception Cohort. Rheumatology. 2018;57(4):677–87. https://doi.org/10.1093/rheumatology/kex444 .
doi: 10.1093/rheumatology/kex444 pubmed: 29361147 pmcid: 5888922
Merrill JT, Immermann F, Whitley M, Zhou T, Hill A, O’Toole M, et al. The biomarkers of Lupus Disease Study: a bold Approach May mitigate interference of background immunosuppressants in clinical trials. Arthritis Rheumatol. 2017;69(6):1257–66. https://doi.org/10.1002/art.40086 .
doi: 10.1002/art.40086 pubmed: 28257602 pmcid: 5501389
Ruiz-Arruza I, Barbosa C, Ugarte A, Ruiz-Irastorza G. Comparison of high versus low–medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun rev. 2015;14(10):875–9. https://doi.org/10.1016/j.autrev.2015.05.011 .
doi: 10.1016/j.autrev.2015.05.011 pubmed: 26044819
Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15(9):450–4. https://doi.org/10.1016/0167-5699(94)90276-3 .
doi: 10.1016/0167-5699(94)90276-3 pubmed: 7524522
de Sèze J, Maillart E, Gueguen A, Laplaud DA, Michel L, Thouvenot E, et al. Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic. Front Immunol. 2023;14. https://doi.org/10.3389/fimmu.2023.1004795 .
Hiddemann W. Frontline therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725–32. https://doi.org/10.1182/blood-2005-01-0016 .
doi: 10.1182/blood-2005-01-0016 pubmed: 16123223
Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of Rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial. Arthr Rhuem. 2006;54(5):1390–400. https://doi.org/10.1002/art.21778 .
doi: 10.1002/art.21778
Murphy G, Isenberg DA. New therapies for systemic lupus erythematosus — past imperfect, future tense. Nat Rev Rheumatol. 2019;15(7):403–12. https://doi.org/10.1038/s41584-019-0235-5 .
doi: 10.1038/s41584-019-0235-5 pubmed: 31165780
Witt 1 M, Proft MGF, Baeuerle M, Aringer M, Burmester G, Chehab G, Fiehn C, Fischer-Betz R, Fleck M, Freivogel K, Haubitz M, Kötter I, Lovric S, Metzler C, Rubberth-Roth A, Schwarting A, Specker C, Tony H-P, Unger L, Wassenberg S, Dörner T. H Schulze-Koops; German Registry of Autoimmune diseases (GRAID) investigators. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Research Support, Non-US Gov’t. https://doi.org/10.1177/0961203313503912
McCarthy EM, Sutton E, Nesbit S, White J, Parker B, Jayne D, et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology. 2018;57(3):470–9. https://doi.org/10.1093/rheumatology/kex395 .
doi: 10.1093/rheumatology/kex395 pubmed: 29216396
Aguirre-Alastuey QdaCR, Isenberg ME, Saracino DA. Assessment of response to B-Cell depletion using Rituximab in Cutaneous Lupus Erythematosus. JAMA Dermatology. 2018;154(12). https://doi.org/10.1001/jamadermatol.2018.3793 .
Md Yusof MY, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017;76(11):1829–36. https://doi.org/10.1136/annrheumdis-2017-211191 .
doi: 10.1136/annrheumdis-2017-211191 pubmed: 28684557
van Schaik M, Arends EJ, Soonawala D, van Ommen E, de Leeuw K, Limper M, et al. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label synbiose 2 trial. Trials. 2022;23(1). https://doi.org/10.1186/s13063-022-06874-w .
Genovese MC, Kaine JL, Lowenstein MB, Giudice JD, Baldassare A, Schechtman J, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study. Arthr Rhuem. 2008;58(9):2652–61. https://doi.org/10.1002/art.23732 .
doi: 10.1002/art.23732
Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of Ocrelizumab in active proliferative lupus nephritis: results from a Randomized, Double-Blind, phase III study. Arthr Rhuem. 2013;65(9):2368–79. https://doi.org/10.1002/art.38037 .
doi: 10.1002/art.38037
Reddy V, Klein C, Isenberg DA, Glennie MJ, Cambridge G, Cragg MS, et al. Obinutuzumab induces superior B-cell cytotoxicity to Rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology. 2017;56(7):1227–37. https://doi.org/10.1093/rheumatology/kex067 .
doi: 10.1093/rheumatology/kex067 pubmed: 28407142 pmcid: 5808665
Kumar A, Planchais C, Fronzes R, Mouquet H, Reyes N. Binding mechanisms of therapeutic antibodies to human CD20. Science. 2020;369(6505):793–9. https://doi.org/10.1126/science.abb8008 .
doi: 10.1126/science.abb8008 pubmed: 32792392
Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182(1):29–45. https://doi.org/10.1111/bjh.15232 .
doi: 10.1111/bjh.15232 pubmed: 29741753
Masoud S, McAdoo SP, Bedi R, Cairns TD, Lightstone L. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to Rituximab. Rheumatology. 2018;57(7):1156–61. https://doi.org/10.1093/rheumatology/key042 .
doi: 10.1093/rheumatology/key042 pubmed: 29562252
Haarhaus ML, Svenungsson E, Gunnarsson I. Ofatumumab treatment in lupus nephritis patients. Clin Kidney J. 2016;9(4):552–5. https://doi.org/10.1093/ckj/sfw022 .
doi: 10.1093/ckj/sfw022 pubmed: 27478595 pmcid: 4957712
Lei L, Muhammad S, Al-Obaidi M, Sebire N, Cheng IL, Eleftheriou D et al. Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C δ. Pedia Rheumatol. 2018;16(1). https://doi.org/10.1186/s12969-018-0278-1 .
Cinar OK, Marlais M, Al Obaidi M, Cheng IL, Tullus K, Brogan P, et al. Ofatumumab use in juvenile systemic lupus erythematosus: a single centre experience. Lupus. 2020;30(3):527–30. https://doi.org/10.1177/0961203320981137 .
doi: 10.1177/0961203320981137 pubmed: 33327846
Chan VS-F, Tsang HH-L, Tam RC-Y, Lu L, Lau C-S. B-cell-targeted therapies in systemic lupus erythematosus. Cell Mol Immunol. 2013;10(2):133–42. https://doi.org/10.1038/cmi.2012.64 .
doi: 10.1038/cmi.2012.64 pubmed: 23455017 pmcid: 4003049
Chu SY, Yeter K, Kotha R, Pong E, Miranda Y, Phung S, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an Anti-CD19 antibody that coengages B Cell Antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheumatol. 2014;66(5):1153–64. https://doi.org/10.1002/art.38334 .
doi: 10.1002/art.38334 pubmed: 24782179
Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, et al. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies. Mol Immunol. 2008;45(15):3926–33. https://doi.org/10.1016/j.molimm.2008.06.027 .
doi: 10.1016/j.molimm.2008.06.027 pubmed: 18691763
Szili D, Cserhalmi M, Bankó Z, Nagy G, Szymkowski DE, Sármay G. Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19. mAbs. 2014;6(4):991–9. https://doi.org/10.4161/mabs.28841 .
doi: 10.4161/mabs.28841 pubmed: 24828435 pmcid: 4171032
Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IWL, et al. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic Lupus Erythematosus. J Immunol. 2011;186(7):4223–33. https://doi.org/10.4049/jimmunol.1003412 .
doi: 10.4049/jimmunol.1003412 pubmed: 21357255
Chen D, Ireland SJ, Davis LS, Kong X, Stowe AM, Wang Y, et al. Autoreactive CD19 + CD20 – plasma cells contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis. J Immunol. 2016;196(4):1541–9. https://doi.org/10.4049/jimmunol.1501376 .
doi: 10.4049/jimmunol.1501376 pubmed: 26764035
Mougiakakos D, Kronke G, Volkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T cells in refractory systemic Lupus Erythematosus. N Engl J Med. 2021;385(6):567–9. https://doi.org/10.1056/NEJMc2107725 .
doi: 10.1056/NEJMc2107725 pubmed: 34347960
Traczewski P, Rudnicka L. Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol. 2011;71(2):175. https://doi.org/10.1111/j.1365-2125.2010.03767.x .
doi: 10.1111/j.1365-2125.2010.03767.x pubmed: 21219397 pmcid: 3040537
Clark EA, Giltiay NV. CD22: A Regulator of Innate and adaptive B cell responses and autoimmunity. Front Immunol. 2018;9:9. https://doi.org/10.3389/fimmu.2018.02235 .
doi: 10.3389/fimmu.2018.02235
Santiago M-L, Mary C, Parzy D, Jacquet C, Montagutelli X, Parkhouse RME, et al. Linkage of a major quantitative trait locus toYaa gene-induced lupus-like nephritis in (NZW × C57BL/6)F1 mice. Eur J Immunol. 1998;28(12):4257–67. https://doi.org/10.1002/(sici)1521-4141(199812)28:12<4257::Aid-immu4257>3.0.Co;2-h .
doi: 10.1002/(sici)1521-4141(199812)28:12<4257::Aid-immu4257>3.0.Co;2-h pubmed: 9862363
Mary C, Laporte C, Parzy D, Santiago M-L, Stefani F, Lajaunias Fdr, et al. Cd22aPRE-mRNA dysregulated expression of theCd22Gene as a result of a short interspersed nucleotide element insertion inCd22aLupus-prone mice. J Immunol. 2000;165(6):2987–96. https://doi.org/10.4049/jimmunol.165.6.2987 .
doi: 10.4049/jimmunol.165.6.2987 pubmed: 10975807
O’Keefe TL, Williams GT, Batista FD, Neuberger MS. Deficiency in CD22, a B cell–specific inhibitory receptor, is sufficient to predispose to Development of High Affinity autoantibodies. J Exp Med. 1999;189(8):1307–13. https://doi.org/10.1084/jem.189.8.1307 .
doi: 10.1084/jem.189.8.1307 pubmed: 10209047 pmcid: 2193034
Geh D, Gordon C. Epratuzumab for the treatment of systemic lupus erythematosus. Expert Rev Clin Immunol. 2018;14(4):245–58. https://doi.org/10.1080/1744666x.2018.1450141 .
doi: 10.1080/1744666x.2018.1450141 pubmed: 29542345
Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73(1):183–90. https://doi.org/10.1136/annrheumdis-2012-202760 .
doi: 10.1136/annrheumdis-2012-202760 pubmed: 23313811
Clowse MEB, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, et al. Efficacy and safety of Epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, Double-Blind, Placebo‐controlled trials. Arthritis Rheumatol. 2017;69(2):362–75. https://doi.org/10.1002/art.39856 .
doi: 10.1002/art.39856 pubmed: 27598855 pmcid: 5299488
Burns M, Ostendorf L, Biesen R, Grützkau A, Hiepe F, Mei HE, et al. Dysregulated CD38 expression on Peripheral Blood Immune Cell subsets in SLE. Int J Mol Sci. 2021;22(5): 2424. https://doi.org/10.3390/ijms22052424 .
doi: 10.3390/ijms22052424 pubmed: 33670902 pmcid: 7957821
Parodis I, Gatto M, Sjöwall C. B cells in systemic lupus erythematosus: targets of new therapies and surveillance tools. Front Med. 2022;9:9. https://doi.org/10.3389/fmed.2022.952304 .
doi: 10.3389/fmed.2022.952304
Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, et al. Targeting CD38 with Daratumumab in Refractory systemic lupus erythematosus. N Engl J Med. 2020;383(12):1149–55. https://doi.org/10.1056/NEJMoa2023325 .
doi: 10.1056/NEJMoa2023325 pubmed: 32937047
Holzer M-T, Ruffer N, Huber TB, Kötter I, Ostendorf L, Krusche M. Daratumumab for autoimmune diseases: a systematic review. RMD Open. 2023;9(4): e003604. https://doi.org/10.1136/rmdopen-2023-003604 .
doi: 10.1136/rmdopen-2023-003604 pubmed: 38101819 pmcid: 10729190
Korver W, Carsillo M, Yuan J, Idamakanti N, Wagoner M, Shi P, et al. A reduction in B, T, and natural killer cells expressing CD38 by TAK-079 inhibits the induction and progression of Collagen-Induced Arthritis in Cynomolgus monkeys. J Pharmacol Exp Ther. 2019;370(2):182–96. https://doi.org/10.1124/jpet.119.256602 .
doi: 10.1124/jpet.119.256602 pubmed: 31085699
Fedyk ER, Zhao L, Koch A, Smithson G, Estevam J, Chen G, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK‐079 in healthy subjects. Br J Clin Pharmacol. 2020;86(7):1314–25. https://doi.org/10.1111/bcp.14241 .
doi: 10.1111/bcp.14241 pubmed: 32045493 pmcid: 7319013
McDonnell SRP, Nguyen VA, Walton NM, Merkwirth C, Hong F, Berg D, et al. Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus Sci Med. 2024;11(1): e001112. https://doi.org/10.1136/lupus-2023-001112 .
doi: 10.1136/lupus-2023-001112 pubmed: 38453421 pmcid: 10921479
Smulski CR, Eibel H. BAFF and BAFF-Receptor in B Cell Selection and Survival. Front Immunol. 2018;9:9. https://doi.org/10.3389/fimmu.2018.02285 .
doi: 10.3389/fimmu.2018.02285
Nakayamada S, Tanaka Y. BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflamm Regeneration. 2016;36(1). https://doi.org/10.1186/s41232-016-0015-4 .
Gupta M, Dillon SR, Ziesmer SC, Feldman AL, Witzig TE, Ansell SM, et al. A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. Blood. 2009;113(21):5206–16. https://doi.org/10.1182/blood-2008-09-179762 .
doi: 10.1182/blood-2008-09-179762 pubmed: 19321861 pmcid: 2686190
Zhang K, Roy NK, Vicioso Y, Woo J, Beck R, de Lima M, et al. BAFF receptor antibody for mantle cell lymphoma therapy. OncoImmunology. 2021;10(1): 1893501. https://doi.org/10.1080/2162402x.2021.1893501 .
doi: 10.1080/2162402x.2021.1893501 pubmed: 33747637 pmcid: 7939563
Zhang F, Bae S-C, Bass D, Chu M, Egginton S, Gordon D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77(3):355–63. https://doi.org/10.1136/annrheumdis-2017-211631 .
doi: 10.1136/annrheumdis-2017-211631 pubmed: 29295825
Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. Efficacy and safety of Subcutaneous Belimumab in systemic lupus erythematosus: a fifty-two–week randomized, Double‐Blind, Placebo‐Controlled Study. Arthritis Rheumatol. 2017;69(5):1016–27. https://doi.org/10.1002/art.40049 .
doi: 10.1002/art.40049 pubmed: 28118533 pmcid: 5434872
Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201–10. https://doi.org/10.1002/art.27189 .
doi: 10.1002/art.27189 pubmed: 20039404 pmcid: 2857977
Möckel T, Basta F, Weinmann-Menke J, Schwarting A. B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic Lupus Erythematosus (SLE). Autoimmun rev. 2021;20(2): 102736. https://doi.org/10.1016/j.autrev.2020.102736 .
doi: 10.1016/j.autrev.2020.102736 pubmed: 33333233
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31. https://doi.org/10.1016/s0140-6736(10)61354-2 .
doi: 10.1016/s0140-6736(10)61354-2 pubmed: 21296403
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthr Rhuem. 2011;63(12):3918–30. https://doi.org/10.1002/art.30613 .
doi: 10.1002/art.30613
Oon S, Huq M, Golder V, Ong PX, Morand EF, Nikpour M. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis. 2019;78(5):629–33. https://doi.org/10.1136/annrheumdis-2018-214427 .
doi: 10.1136/annrheumdis-2018-214427 pubmed: 30679152
Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615–21. https://doi.org/10.1136/annrheumdis-2015-207726 .
doi: 10.1136/annrheumdis-2015-207726 pubmed: 26458737
Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, et al. Early Disease and Low Baseline Damage as predictors of response to Belimumab in patients with systemic Lupus Erythematosus in a real-life setting. Arthritis Rheumatol. 2020;72(8):1314–24. https://doi.org/10.1002/art.41253 .
doi: 10.1002/art.41253 pubmed: 32275125
Nilforoushzadeh MA, Heidari N, Heidari A, Ghane Y, Lotfi Z, Jaffary F, et al. The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review. Int Immunopharmacol. 2024;131:131. https://doi.org/10.1016/j.intimp.2024.111827 .
doi: 10.1016/j.intimp.2024.111827
Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):323–31. https://doi.org/10.1136/annrheumdis-2015-207653 .
doi: 10.1136/annrheumdis-2015-207653 pubmed: 26338095
Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):332–40. https://doi.org/10.1136/annrheumdis-2015-207654 .
doi: 10.1136/annrheumdis-2015-207654 pubmed: 26293163
Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006–15. https://doi.org/10.1136/annrheumdis-2013-205067 .
doi: 10.1136/annrheumdis-2013-205067 pubmed: 24951103
Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, et al. Efficacy and safety of atacicept in patients with systemic Lupus Erythematosus. Arthritis Rheumatol. 2018;70(2):266–76. https://doi.org/10.1002/art.40360 .
doi: 10.1002/art.40360 pubmed: 29073347 pmcid: 6099253
Furie RA, Bruce IN, Dörner T, Leon MG, Leszczyński P, Urowitz M, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology. 2021;60(11):5397–407. https://doi.org/10.1093/rheumatology/keab381 .
doi: 10.1093/rheumatology/keab381 pubmed: 33956056 pmcid: 9194804
Dai H, Fan Q, Wang C. Recent applications of immunomodulatory biomaterials for disease immunotherapy. Explor (Beijing China). 2022;2(6): 20210157. https://doi.org/10.1002/exp.20210157 .
doi: 10.1002/exp.20210157
Du S, Yan J, Xue Y, Zhong Y, Dong Y. Adoptive cell therapy for cancer treatment. Explor (Beijing China). 2023;3(4): 20210058. https://doi.org/10.1002/exp.20210058 .
doi: 10.1002/exp.20210058
Tsang-A-Sjoe MWP, Bultink IEM. New developments in systemic lupus erythematosus. Rheumatology. 2021;60(Supplement6):vi21-28. https://doi.org/10.1093/rheumatology/keab498 .
doi: 10.1093/rheumatology/keab498 pubmed: 34951924 pmcid: 8709564
Michel NA, Zirlik A, Wolf D. CD40L and its receptors in Atherothrombosis—An update. Front Cardiovasc Med. 2017. https://doi.org/10.3389/fcvm.2017.00040 .
doi: 10.3389/fcvm.2017.00040 pubmed: 28824922 pmcid: 5539175
Soybilgic A. Biologic agents and other emerging therapies for childhood SLE. Pediatr Ann. 2022;51(2). https://doi.org/10.3928/19382359-20220118-01 .
Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-Mediated inhibition in regulation of T cell responses: mechanisms and manipulation in Tumor Immunotherapy. Annu Rev Immunol. 2001;19(1):565–94. https://doi.org/10.1146/annurev.immunol.19.1.565 .
doi: 10.1146/annurev.immunol.19.1.565 pubmed: 11244047
Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19(1):225–52. https://doi.org/10.1146/annurev.immunol.19.1.225 .
doi: 10.1146/annurev.immunol.19.1.225 pubmed: 11244036
Davidson A, Diamond B, Wofsy D, Daikh D. Block and tackle: CTLA4Ig takes on lupus. Lupus. 2016;14(3):197–203. https://doi.org/10.1191/0961203305lu2136oa .
doi: 10.1191/0961203305lu2136oa
Nurieva RI, Liu X, Dong C. Yin–Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev. 2009;229(1):88–100. https://doi.org/10.1111/j.1600-065X.2009.00769.x .
doi: 10.1111/j.1600-065X.2009.00769.x pubmed: 19426216 pmcid: 2875245
Ford ML, Adams AB, Pearson TC. Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol. 2013;10(1):14–24. https://doi.org/10.1038/nrneph.2013.183 .
doi: 10.1038/nrneph.2013.183 pubmed: 24100403 pmcid: 4365450
Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. OncoImmunology. 2014;1(8):1223–5. https://doi.org/10.4161/onci.21335 .
doi: 10.4161/onci.21335
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–42. https://doi.org/10.1038/nri3405 .
doi: 10.1038/nri3405 pubmed: 23470321 pmcid: 3786574
Choi Youn S, Kageyama R, Eto D, Escobar Tania C, Johnston Robert J, Monticelli L, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity. 2011;34(6):932–46. https://doi.org/10.1016/j.immuni.2011.03.023 .
doi: 10.1016/j.immuni.2011.03.023 pubmed: 21636296 pmcid: 3124577
Weber JP, Fuhrmann F, Feist RK, Lahmann A, Al Baz MS, Gentz L-J, et al. ICOS maintains the T follicular helper cell phenotype by down-regulating Krüppel-like factor 2. J Exp Med. 2015;212(2):217–33. https://doi.org/10.1084/jem.20141432 .
doi: 10.1084/jem.20141432 pubmed: 25646266 pmcid: 4322049
Straub RH, Härle P, Yamana S, Matsuda T, Takasugi K, Kishimoto T, et al. Anti–interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double‐blind, placebo‐controlled study. Arthr Rhuem. 2006;54(6):1778–85. https://doi.org/10.1002/art.21826 .
doi: 10.1002/art.21826
Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage‐escalation study. Arthr Rhuem. 2010;62(2):542–52. https://doi.org/10.1002/art.27221 .
doi: 10.1002/art.27221
Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti‐IL‐6 monoclonal antibody (sirukumab) in healthy subjects in a first‐in‐human study. Br J Clin Pharmacol. 2011;72(2):270–81. https://doi.org/10.1111/j.1365-2125.2011.03964.x .
doi: 10.1111/j.1365-2125.2011.03964.x pubmed: 21392075 pmcid: 3162657
Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, et al. Phase I, randomized, double-blind, placebo‐controlled, multiple intravenous, dose‐ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthr Rhuem. 2013;65(10):2661–71. https://doi.org/10.1002/art.38091 .
doi: 10.1002/art.38091
Maeda K, Malykhin A, Teague-Weber BN, Sun X-H, Farris AD, Coggeshall KM. Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus–prone B6.Sle1.Yaa animals. Blood. 2009;113(19):4534–40. https://doi.org/10.1182/blood-2008-12-192559 .
doi: 10.1182/blood-2008-12-192559 pubmed: 19224760 pmcid: 2680362
Rovin BH, van Vollenhoven RF, Aranow C, Wagner C, Gordon R, Zhuang Y, et al. A Multicenter, Randomized, Double-Blind, Placebo‐Controlled Study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active Lupus Nephritis. Arthritis Rheumatol. 2016;68(9):2174–83. https://doi.org/10.1002/art.39722 .
doi: 10.1002/art.39722 pubmed: 27110697 pmcid: 5129491
Ma X, Nakayamada S, Kubo S, Sakata K, Yamagata K, Miyazaki Y, et al. Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors. Ann Rheum Dis. 2018;77(9):1354–61. https://doi.org/10.1136/annrheumdis-2017-212652 .
doi: 10.1136/annrheumdis-2017-212652 pubmed: 29853448
van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392(10155):1330–9. https://doi.org/10.1016/s0140-6736(18)32167-6 .
doi: 10.1016/s0140-6736(18)32167-6 pubmed: 30249507
van Vollenhoven RF, Kalunian KC, Dörner T, Hahn BH, Tanaka Y, Gordon RM, et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis. 2022;81(11):1556–63. https://doi.org/10.1136/ard-2022-222858 .
doi: 10.1136/ard-2022-222858 pubmed: 35798534
Ohl K, Tenbrock K, Tsokos G. Inflammatory cytokines in systemic Lupus Erythematosus. Biomed Res Int. 2011;2011(1). https://doi.org/10.1155/2011/432595 .
Eloranta M-L, Rönnblom L. Cause and consequences of the activated type I interferon system in SLE. J Mol Med. 2016;94(10):1103–10. https://doi.org/10.1007/s00109-016-1421-4 .
doi: 10.1007/s00109-016-1421-4 pubmed: 27094810
Viallard JF, Pellegrin JL, Ranchin V, Schaeverbeke T, Dehais J, Longy-Boursier M, et al. Th1 (IL-2, interferon-gamma (IFN-γ)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1999;115(1):189–95. https://doi.org/10.1046/j.1365-2249.1999.00766.x .
doi: 10.1046/j.1365-2249.1999.00766.x pubmed: 9933441 pmcid: 1905189
Paradowska-Gorycka A, Wajda A, Stypinska B, Walczuk E, Rzeszotarska E, Walczyk M, et al. Variety of endosomal TLRs and interferons (IFN-α, IFN-β, IFN-γ) expression profiles in patients with SLE, SSc and MCTD. Clin Exp Immunol. 2021;204(1):49–63. https://doi.org/10.1111/cei.13566 .
doi: 10.1111/cei.13566 pubmed: 33336388 pmcid: 7944358
Al-Janadi M, Al-Balla S, Al-Dalaan A, Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol. 1993;13(1):58–67. https://doi.org/10.1007/bf00920636 .
doi: 10.1007/bf00920636 pubmed: 8445045
Yang BC, Wang YS, Lin LC, Liu MF. Induction of apoptosis and cytokine gene expression in T-Cell lines by Sera of patients with systemic Lupus Erythematosus. Scand J Immunol. 2003;45(1):96–102. https://doi.org/10.1046/j.1365-3083.1997.d01-371.x .
doi: 10.1046/j.1365-3083.1997.d01-371.x
Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75(11):2014–21. https://doi.org/10.1136/annrheumdis-2015-208140 .
doi: 10.1136/annrheumdis-2015-208140 pubmed: 27088255
Welcher AA, Boedigheimer M, Kivitz AJ, Amoura Z, Buyon J, Rudinskaya A, et al. Blockade of Interferon-γ normalizes Interferon‐Regulated Gene expression and serum CXCL10 levels in patients with systemic Lupus Erythematosus. Arthritis Rheumatol. 2015;67(10):2713–22. https://doi.org/10.1002/art.39248 .
doi: 10.1002/art.39248 pubmed: 26138472 pmcid: 5054935
Chen P, Vu T, Narayanan A, Sohn W, Wang J, Boedigheimer M, et al. Pharmacokinetic and pharmacodynamic relationship of AMG 811, an Anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic Lupus Erythematosus. Pharm Res. 2014;32(2):640–53. https://doi.org/10.1007/s11095-014-1492-2 .
doi: 10.1007/s11095-014-1492-2 pubmed: 25213774
Werth VP, Fiorentino D, Sullivan BA, Boedigheimer MJ, Chiu K, Wang C, et al. Brief report: Pharmacodynamics, Safety, and clinical efficacy of AMG 811, a human anti–Interferon-γ antibody, in patients with Discoid Lupus Erythematosus. Arthritis Rheumatol. 2017;69(5):1028–34. https://doi.org/10.1002/art.40052 .
doi: 10.1002/art.40052 pubmed: 28118537 pmcid: 5434930
Boedigheimer MJ, Martin DA, Amoura Z, Sánchez-Guerrero J, Romero-Diaz J, Kivitz A, et al. Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Sci Med. 2017;4(1): e000226. https://doi.org/10.1136/lupus-2017-000226 .
doi: 10.1136/lupus-2017-000226 pubmed: 29018537 pmcid: 5604705
O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, Immunodeficiency, and Cancer. N Engl J Med. 2013;368(2):161–70. https://doi.org/10.1056/NEJMra1202117 .
doi: 10.1056/NEJMra1202117 pubmed: 23301733 pmcid: 7604876
Dean GS. Cytokines and systemic lupus erythematosus. Ann Rheum Dis. 2000;59(4):243–51. https://doi.org/10.1136/ard.59.4.243 .
doi: 10.1136/ard.59.4.243 pubmed: 10733469 pmcid: 1753117
Alunno A, Padjen I, Fanouriakis A, Boumpas DT. Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic Lupus Erythematosus: integration of distinct inflammatory pathways and the Prospect of their inhibition with an oral Agent. Cells. 2019;8(8): 898. https://doi.org/10.3390/cells8080898 .
doi: 10.3390/cells8080898 pubmed: 31443172 pmcid: 6721755
Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, et al. Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. Arthritis Rheumatol. 2016;69(1):148–60. https://doi.org/10.1002/art.39818 .
doi: 10.1002/art.39818
You H, Zhang G, Wang Q, Zhang S, Zhao J, Tian X, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019;78(10):1441–3. https://doi.org/10.1136/annrheumdis-2019-215455 .
doi: 10.1136/annrheumdis-2019-215455 pubmed: 31005902
Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222–31. https://doi.org/10.1016/s0140-6736(18)31363-1 .
doi: 10.1016/s0140-6736(18)31363-1 pubmed: 30043749
Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, Randomized, Double-Blind, placebo-controlled trial. Arthritis Rheumatol. 2023;75(2):242–52. https://doi.org/10.1002/art.42391 .
doi: 10.1002/art.42391 pubmed: 36369798
Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1): 3391. https://doi.org/10.1038/s41467-021-23361-z .
doi: 10.1038/s41467-021-23361-z pubmed: 34099646 pmcid: 8185103
Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of JAK1 and JAK2 is efficacious in Rodent models of Arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298–307. https://doi.org/10.4049/jimmunol.0902819 .
doi: 10.4049/jimmunol.0902819 pubmed: 20363976
Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discovery. 2017;16(12):843–62. https://doi.org/10.1038/nrd.2017.201 .
doi: 10.1038/nrd.2017.201 pubmed: 29104284
Dörner T, Tanaka Y, Dow ER, Koch AE, Silk M, Ross Terres JA, et al. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Ann Rheum Dis. 2022;81(9):1267–72. https://doi.org/10.1136/annrheumdis-2022-222335 .
doi: 10.1136/annrheumdis-2022-222335 pubmed: 35609978
Werth VP, Fleischmann R, Robern M, Touma Z, Tiamiyu I, Gurtovaya O, et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology. 2022;61(6):2413–23. https://doi.org/10.1093/rheumatology/keab685 .
doi: 10.1093/rheumatology/keab685 pubmed: 34498056
Weichhart T, Hengstschläger M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol. 2015;15(10):599–614. https://doi.org/10.1038/nri3901 .
doi: 10.1038/nri3901 pubmed: 26403194 pmcid: 6095456
Perl A. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci. 2015;1346(1):33–44. https://doi.org/10.1111/nyas.12756 .
doi: 10.1111/nyas.12756 pubmed: 25907074 pmcid: 4480196
Oaks Z, Perl A. Metabolic control of the epigenome in systemic Lupus erythematosus. Autoimmunity. 2013;47(4):256–64. https://doi.org/10.3109/08916934.2013.834495 .
doi: 10.3109/08916934.2013.834495 pubmed: 24128087 pmcid: 4034124
Zhao M, Wang J, Liao W, Li D, Li M, Wu H, et al. Increased 5-hydroxymethylcytosine in CD4 + T cells in systemic lupus erythematosus. J Autoimmun. 2016;69:64–73. https://doi.org/10.1016/j.jaut.2016.03.001 .
doi: 10.1016/j.jaut.2016.03.001 pubmed: 26984631
Koga T, Hedrich CM, Mizui M, Yoshida N, Otomo K, Lieberman LA, et al. CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance. J Clin Invest. 2014;124(5):2234–45. https://doi.org/10.1172/jci73411 .
doi: 10.1172/jci73411 pubmed: 24667640 pmcid: 4001553
Lai Z-W, Borsuk R, Shadakshari A, Yu J, Dawood M, Garcia R, et al. Mechanistic target of Rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic Lupus Erythematosus. J Immunol. 2013;191(5):2236–46. https://doi.org/10.4049/jimmunol.1301005 .
doi: 10.4049/jimmunol.1301005 pubmed: 23913957
Kshirsagar S, Riedl M, Billing H, Tönshoff B, Thangavadivel S, Steuber C, et al. Akt-dependent enhanced migratory capacity of Th17 cells from children with Lupus Nephritis. J Immunol. 2014;193(10):4895–903. https://doi.org/10.4049/jimmunol.1400044 .
doi: 10.4049/jimmunol.1400044 pubmed: 25339666
Perl A, Hanczko R, Lai Z-W, Oaks Z, Kelly R, Borsuk R, et al. Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. Metabolomics. 2015;11(5):1157–74. https://doi.org/10.1007/s11306-015-0772-0 .
doi: 10.1007/s11306-015-0772-0 pubmed: 26366134 pmcid: 4559110
Sehgal SN, Bansbach CC. Rapamycin: in vitro profile of a new immunosuppressive macrolide. Ann New York Acad Sci. 2006;685(1):58–67. https://doi.org/10.1111/j.1749-6632.1993.tb35852.x .
doi: 10.1111/j.1749-6632.1993.tb35852.x
Fernandez DR, Telarico T, Bonilla E, Li Q, Banerjee S, Middleton FA, et al. Activation of mammalian target of Rapamycin controls the loss of TCRζ in Lupus T Cells through HRES-1/Rab4-Regulated lysosomal degradation. J Immunol. 2009;182(4):2063–73. https://doi.org/10.4049/jimmunol.0803600 .
doi: 10.4049/jimmunol.0803600 pubmed: 19201859
Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78(1):35–43. https://doi.org/10.1016/0092-8674(94)90570-3 .
doi: 10.1016/0092-8674(94)90570-3 pubmed: 7518356
Warner LM, Adams LM, Sehgal SN. Rapamycin Prolongs Survival and arrests pathophysiologic changes in murine systemic Lupus Erythematosus. Arthr Rhuem. 2005;37(2):289–97. https://doi.org/10.1002/art.1780370219 .
doi: 10.1002/art.1780370219
Caza TN, Fernandez DR, Talaber G, Oaks Z, Haas M, Madaio MP, et al. HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. Ann Rheum Dis. 2014;73(10):1888–97. https://doi.org/10.1136/annrheumdis-2013-203794 .
doi: 10.1136/annrheumdis-2013-203794 pubmed: 23897774
Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation–induced calcium fluxing in patients with systemic lupus erythematosus. Arthr Rhuem. 2006;54(9):2983–8. https://doi.org/10.1002/art.22085 .
doi: 10.1002/art.22085
Heo YA. Voclosporin: first approval. Drugs. 2021;81(5):605–10. https://doi.org/10.1007/s40265-021-01488-z .
doi: 10.1007/s40265-021-01488-z pubmed: 33788181 pmcid: 8010786
Rovin BH, Solomons N, Pendergraft WF, Dooley MA, Tumlin J, Romero-Diaz J, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95(1):219–31. https://doi.org/10.1016/j.kint.2018.08.025 .
doi: 10.1016/j.kint.2018.08.025 pubmed: 30420324
Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al. Anifrolumab, an anti–Interferon-α receptor monoclonal antibody, in moderate‐to‐severe systemic Lupus Erythematosus. Arthritis Rheumatol. 2017;69(2):376–86. https://doi.org/10.1002/art.39962 .
doi: 10.1002/art.39962 pubmed: 28130918 pmcid: 5299497
Hunter DJ. Uncertainty in the era of Precision Medicine. N Engl J Med. 2016;375(8):711–3. https://doi.org/10.1056/NEJMp1608282 .
doi: 10.1056/NEJMp1608282 pubmed: 27557298
Aringer M. EULAR/ACR classification criteria for SLE. Semin Arthritis Rheum. 2019;49(3):S14-7. https://doi.org/10.1016/j.semarthrit.2019.09.009 .
doi: 10.1016/j.semarthrit.2019.09.009 pubmed: 31779843
Kubo S, Nakayamada S, Yoshikawa M, Miyazaki Y, Sakata K, Nakano K, et al. Peripheral immunophenotyping identifies three subgroups based on T cell heterogeneity in Lupus patients. Arthritis Rheumatol. 2017;69(10):2029–37. https://doi.org/10.1002/art.40180 .
doi: 10.1002/art.40180 pubmed: 28605137

Auteurs

Xu Su (X)

Medical Research Center, College of Medicine, The Third People's Hospital of Chengdu (Affiliated Hospital of Southwest Jiaotong University, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China.

Hui Yu (H)

Department of Urology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu, 610014, China.

Qingqiang Lei (Q)

Center of Bone Metabolism and Repair, Department of Wound Repair and Rehabilitation Medicine, State Key Laboratory of Trauma, Burns and Combined Injury, Trauma Center, Research Institute of Surgery, Daping Hospital, Army Medical University, Chongqing, 400000, China.

Xuerui Chen (X)

Medical Research Center, College of Medicine, The Third People's Hospital of Chengdu (Affiliated Hospital of Southwest Jiaotong University, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China.

Yanli Tong (Y)

Université Paris Cité, INSERM U1151, CNRS UMR8253, Institut Necker Enfants Malades, Paris, F-75015, France.

Zhongyang Zhang (Z)

Department of Health Technology, The Danish National Research Foundation and Villum Foundation's Center IDUN, Technical University of Denmark, Kgs. Lyngby, Denmark.

Wenyong Yang (W)

Medical Research Center, College of Medicine, The Third People's Hospital of Chengdu (Affiliated Hospital of Southwest Jiaotong University, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China. ywenyong@hotmail.com.
Department of Neurosurgery, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu, 610014, China. ywenyong@hotmail.com.

Yuanbiao Guo (Y)

Medical Research Center, College of Medicine, The Third People's Hospital of Chengdu (Affiliated Hospital of Southwest Jiaotong University, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China. guoyuanbiao@swjtu.edu.cn.

Liangbin Lin (L)

Medical Research Center, College of Medicine, The Third People's Hospital of Chengdu (Affiliated Hospital of Southwest Jiaotong University, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China. linliangbin333@163.com.
Obesity and Metabolism Medicine-Engineering Integration Laboratory, Department of General Surgery, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu, 610031, China. linliangbin333@163.com.
The Center of Gastrointestinal and Minimally Invasive Surgery, Department of General Surgery, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu, 610031, China. linliangbin333@163.com.
ORCID: 0000-0003-0455-2569

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Systemic lupus erythematosus: pathogenesis and...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Lupus érythémateux disséminé › Systemic lupus erythematosus: pathogenesis and...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Thérapie moléculaire ciblée › Systemic lupus erythematosus: pathogenesis and...
questionsmedicales.fr › Eucaryotes › Animaux › Systemic lupus erythematosus: pathogenesis and...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunosuppresseurs › Systemic lupus erythematosus: pathogenesis and...